1. Introduction
===============

It has been estimated that by 2020, the number of new cases of cancer will increase to more than 15 million, with the number of deaths increasing to 12 million worldwide.^\[[@R1]\]^ Digestive system cancers are the most common malignant tumors in the world with three million new cases adding each year (accounting for nearly 30% of all cancers).^\[[@R1]\]^ The incidence of digestive system cancers will constantly increase, mainly due to trends in gastric cancer and colorectal cancer.^\[[@R2]\]^ In the majority of developing countries, increasing trends in mortality rates associated with digestive system cancers have also been observed.^\[[@R3],[@R4]\]^

Although increasing evidence has implicated omega-3 polyunsaturated fatty acids (PUFAs) in delaying the progression of anxiety,^\[[@R5]\]^ cardiovascular disease,^\[[@R6]\]^ and polycystic ovary syndrome,^\[[@R7]\]^ their role in cancer etiology has yet to be established. Some observational epidemiological studies^\[[@R8]--[@R10]\]^ have investigated the relationship between long-chain omega-3 PUFAs and the risk of cancers; however, the findings remain controversial. One previous meta-analysis^\[[@R11]\]^ indicated that there was a null association between n-3 PUFAs and the risk of colorectal cancer. However, two systematic reviews of omega-3 PUFAs and cancer risk qualitatively concluded that there is inadequate^\[[@R12]\]^ or limited evidence^\[[@R13]\]^ to suggest an association between long-chain omega-3 PUFA intake and the risk of digestive system cancers. However, it had only been restricted to some types of cancer in most of these studies, and some cancer types, such as esophageal and oral cavity/pharynx cancers, were not investigated. Therefore, we conducted this comprehensive systematic review and meta-analysis study, in order to explore the relationship between omega-3 PUFA usage and the risk of digestive system cancers.

2. Methods
==========

2.1. Search strategy
--------------------

We followed the reporting standards for systematic reviews and meta-analyses of observational studies described in the Observational Studies in Epidemiology (MOOSE) guidelines.^\[[@R14]\]^ For this meta-analysis, three electronic databases including PubMed, Embase, and the Web of Science were used to search from their inception to December 31, 2019, without language restrictions. Reviewing peer-review published articles and computer-aided literature searches using the following search terms with different combinations: ("omega" or "ω-3" or "n-3" or "PUFA" or "fish oil" or "EPA" or "DHA" or "PUFAs" or "eicosapentaenoic acid" or "docosahexaenoic acid" or "linolenic acid" or "docosapentaenoic acid" or "DPA" or "ALA") and ("cancer" or "carcinoma" or "oncology" or "neoplasm") were used to identify the eligible studies. The human studies were restricted in our study. The reference list of any article selected for consideration was manually checked for additional studies.

2.2. Inclusion criteria
-----------------------

We include studies if they met the following criteria:

1.  the study was designed using a case-control or cohort;

2.  the exposure of interest was omega-3 PUFA intake;

3.  the outcome of interest was diagnosed as digestive system cancers or first as digestive system cancers and had died during follow-up in cohort studies;

4.  the study reported estimates of odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) with 95% confidence intervals (CIs) (or information to calculate those effect sizes).

Only the most recent and informative study was included if the same population were published in multiple reports.

2.3. Data extraction and quality assessment
-------------------------------------------

Two independent authors independently reviewed all the included studies. The following information which was extracted from each study using a data collection form: year of publication, the first author\'s name, study design, location, number of cases and participants, sex, types of cancer, exposure definition, risk estimates (ORs, RRs, or HRs) and 95% CIs, and covariates adjusted in the analysis. When data were missing, we contacted the authors for detailed information.

Two reviewers independently assessed the study quality by using the Newcastle--Ottawa Scale (NOS) according to the procedures recommended in the Cochrane Handbook of Systematic Reviews.^\[[@R15]\]^ The NOS was a 9-point scale that allocates points on the basis of the process of selection of the cohort study or case--control study (0--4 points), the comparability (0--2 points), and the identification of outcomes or exposures of study participants (0--3 points). We assigned scores of 0--3, 4--6, and 7--9 for low, moderate, and high quality of studies, respectively. Inter-observer agreement (κ) was 0.892. Any disagreement was resolved by review of the manuscript together to reach consensus.

2.4. Statistical analysis
-------------------------

RRs were used to measure the associations between omega-3 PUFAs and the risk of digestive system cancers, and HRs were considered equivalent to RRs. We combined the case--control and cohort studies in the primary meta-analysis as ORs and RRs provide similar estimates of risk when the outcome was rare.^\[[@R16],[@R17]\]^ Studies reported by different populations or by types of cancer were regarded as independent reports.

A random-effects model was used to estimate the pooled RRs for the relationship between omega-3 PUFAs and the risk of digestive system cancers,^\[[@R18]\]^ if heterogeneity was detected, or the fixed-effects model was used otherwise. The heterogeneity across studies was assessed with *I*^2^ statistic, where value of 25% or less, near 50%, and near 75% or greater as having low, moderate, and high degrees of heterogeneity, respectively.^\[[@R19]\]^ The Egger\'s and Begg\'s tests and inspecting the symmetry of funnel plots were adopted to evaluate publication bias, as recommended by the Cochrane handbook.^\[[@R20],[@R21]\]^ Subgroup analyses were conducted to explore the potential sources of heterogeneity, and were stratified by exposure measurement, study design, sex, study location, cancer site, smoking status, alcohol consumption, body mass index (BMI), and physical activity were conducted to assess the robustness of the results. Additionally, the differences among subgroups were tested using meta-regression analysis (using STATA "metareg" command). Sensitivity analyses were conducted to assess the influence of any single study on the pooled RRs. All statistical analyses were conducted with Stata version 13.0.

3. Results
==========

3.1. Literature search
----------------------

Figure [1](#F1){ref-type="fig"} shows the process of the identification of eligible studies. Of the 5224 articles that were identified, 35 articles qualified for full-text evaluation. Among these articles that underwent full-text review, six articles were duplicate reports from the same study population, eight articles were unmatched with the study exposure, and four studies were added from reference lists ultimately, 25 studies^\[[@R8]--[@R10],[@R22]--[@R43]\]^ with 28 independent reports were included in the meta-analysis.
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3.2. Study characteristics
--------------------------

Table [1](#T1){ref-type="table"}     presents the details of the 25 studies. Overall, data were available from 1,247,271 participants, including 23,173 cases with the following 6 cancer types: oral cavity/pharyngeal cancer (n = 736), esophageal cancer (n = 395), large bowel cancer (n = 2,280), pancreatic cancer (n = 1,132), hepatocellular carcinoma (n = 1,071), and colorectal cancer (n = 16,421). Most studies were performed in North America or Europe^\[[@R9],[@R10],[@R22]--[@R27],[@R29],[@R30],[@R33]--[@R35],[@R37],[@R38],[@R40],[@R42]\]^; seven studies were conducted in Asia,^\[[@R8],[@R28],[@R31],[@R32],[@R36],[@R39],[@R43]\]^ and one was an international study.^\[[@R41]\]^ In total, four studies reported results for women only,^\[[@R33],[@R40],[@R42],[@R43]\]^ two studies reported results for men only,^\[[@R9],[@R41]\]^ six studies^\[[@R26],[@R27],[@R35],[@R36],[@R38],[@R39]\]^ reported results for men and women separately, and 13 studies reported results for both men and women combined.^\[[@R8],[@R10],[@R22]--[@R25],[@R28]--[@R32],[@R34],[@R37]\]^ The average NOS score of the included studies was 7.8 (ranging from 5 to 9).
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3.3. Omega-3 PUFAs and the risk of digestive system cancers
-----------------------------------------------------------

Comparing participants in the highest omega-3 PUFA group with those in the lowest omega-3 PUFA group, the multivariable-adjusted RR for total digestive system cancers was 0.83 (95% CI: 0.76--0.91). There was high heterogeneity across studies (*I*^2^ = 58.0%).

The decreased risks were statistically significant for 4 cancer types: colorectal cancer (RR = 0.89; 95% CI: 0.81--0.98; *I*^2^ = 53.6%), oral cavity/pharyngeal cancer (RR = 0.50; 95% CI: 0.33--0.76), esophageal cancer (RR = 0.50; 95% CI: 0.33--0.76) and large bowel cancer (RR = 0.70; 95% CI: 0.57--0.86). There were no statistically significant associations between omega-3 PUFAs and pancreatic cancer (RR = 0.71; 95% CI: 0.45--1.13; I^2^ = 70.2%) or hepatocellular carcinoma (RR = 0.83; 95% CI: 0.62--1.11; *I*^2^ = 9.5%).

3.4. Subgroup analyses
----------------------

Primary subgroup investigations for digestive system cancers were stratified by region, sex, study design, and type of omega-3 PUFAs; smoking status, alcohol consumption, BMI, and physical activity were controlled or not in the models to examine the stability of the primary results and explore the sources of potential heterogeneity (Table [2](#T2){ref-type="table"}). The differences between n-3 PUFA and in relation to digestive system cancers risk were observed in gender and study design subgroups (*P* values for meta-regression \< .05). However, no significant interactions were found for other stratified variables (all *P* values for interaction \> .05).
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There was a lower risk of digestive system cancers in the case--control studies than in the cohort studies (the pooled RR was 0.69 \[95% CI: 0.61--0.78\] in the case--control studies and the pooled RR was 0.94 \[95% CI: 0.87--1.02\] in the cohort studies) (Table [2](#T2){ref-type="table"}).

The impact of omega-3 PUFAs on the risk of digestive system cancers appeared to be great in the combined sample of men and women (men: RR = 1.02; 95% CI: 0.80--1.30; women: RR = 0.93; 95% CI: 0.84--1.03; combined: RR = 0.79; 95% CI: 0.70--0.89). A decreased risk of digestive system cancers associated with omega-3 PUFA use was also identified in North America and Europe (North America: RR = 0.84; 95% CI: 0.77--0.92; Europe: RR = 0.76; 95% CI: 0.63--0.92). However, no statistically significant association was found in Asian countries (RR = 0.96; 95% CI: 0.84--1.10) (Fig. [2](#F2){ref-type="fig"}).
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The subgroup analysis indicated that an inverse association was observed in the docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) groups (DHA: RR = 0.79; 95% CI: 0.66--0.93; EPA: RR = 0.79; 95% CI: 0.68--0.91), but not in the docosapentaenoic acid' (DPA) and alpha-linolenic acid (ALA) groups (DPA: RR = 0.85; 95% CI: 0.71--1.01; ALA: RR = 0.96; 95% CI: 0.83--1.10).

We conducted subgroup analysis by lifestyle factors. Additional subgroup analyses of lifestyle factors to assess the effect of smoking status, alcohol consumption, BMI, and physical activity on the digestive system cancers relationship showed no differences.

3.5. Sensitivity analyses
-------------------------

We excluded each study one by one and pooled the results of the remaining included studies. The pooled RR of cancer ranged from 0.82 (95% CI, 0.75--0.89) to 0.85 (95% CI, 0.78--0.93), which indicated that none of the studies substantially changed the combined RR.

3.6. Publication bias
---------------------

Visual inspection of a funnel plot did not identify substantial asymmetry (Fig. [3](#F3){ref-type="fig"}). In addition, the Begg\'s test and Egger\'s test provided no evidence of publication bias across included studies (Begg\'s test *P* = .477; Egger\'s test *P* = .334).
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4. Discussion
=============

In this meta-analysis of 25 studies, omega-3 PUFAs exerted a protective effect on the risk of digestive system cancers and was shown to possibly decrease the incident risk of cancers by as much as 17%. Inverse associations were also found between omega-3 PUFAs and the risk of colorectal, oral cavity/pharyngeal, esophageal and large bowel cancers. However, no significant association was observed between the intake of omega-3 PUFAs and the risk of pancreatic and hepatocellular cancers.

There are several potential mechanisms of the anticarcinogenic actions of omega-3 PUFAs. First, omega-3 PUFAs could inhibit the biosynthesis of arachidonic acid-derived eicosanoid, which resulted in an altered immune response to cancer cells and the modulation of inflammation, metastasis, apoptosis, cell proliferation, and angiogenesis.^\[[@R44],[@R45]\]^ Second, omega-3 PUFAs may affect gene expression, the activity of transcription factors, and signal transduction, which contributed to changes in metabolism and cell growth and differentiation.^\[[@R46]\]^ Third, metabolites of omega-3 PUFAs increased the production of PGE3 and decreased the production of PGE2, which was expected to reduce estrogen-stimulated cell growth. Fourth, free radicals and reactive oxygen species could lead to the production of lipid hydroperoxides, which may further lead to genetic damage and cancer, and omega-3 PUFAs have been shown to decrease the levels of free radicals and reactive oxygen species, thus preventing cancer initiation. Final, PUFAs could reduce the risk of cancer through improving insulin sensitivity and membrane fluidity.^\[[@R47]\]^

Our subgroup analyses resulted in three valuable and significant findings. First, an interesting finding was that omega-3 PUFAs reduced the risk of digestive system cancers in the case--control studies but not in the cohort studies. One possible explanation for the difference might be that omega-3 PUFAs were assessed only at baseline in cohort studies, and the single baseline exposure assessment of omega-3 PUFA intake might reduce the ability to identify the relationship between omega-3 PUFAs and digestive system cancers. Moreover, cohort studies were more likely to have potential confounding bias, which might bias the statistical power.^\[[@R48]\]^ Second, our results indicated that the strongest reduction in the risk of digestive system cancers associated with omega-3 PUFA intake was found in North American and European countries. However, no statistical significance was found in Asian countries. The reason may be that more than two-thirds of the included studies were performed in North American and European countries, and only a few studies were conducted in Asian countries, of which, 60% were from Japan. This might affect the accuracy of the results. Therefore, more researches are needed to investigate the differences among different countries and regions. Third, we found that the protective effects on digestive system cancers were observed in DHA and EPA but not in DPA or ALA. Muley et al^\[[@R49]\]^ also indicated that marine n-3 PUFA had a better cardio-protective effects. However, the reasons for the discrepancies remain unclear, and additional studies on investigating the underlying mechanism by which these differences arise are clearly warranted.

This meta-analysis had some strength. This is the first evidence showing that omega-3 PUFAs can decrease the risk of colorectal cancer. Additionally, a large sample size provided reliable results with greater precision and statistical power. Moreover, there was no publication bias in the outcomes, showing that the statistical data obtained from the included studies may approximate actual results. Potential limitations did exist, however, which should be noted. Due to the limitation of the included data, we did not conduct a dose--response relationship analysis; thus, the relationship between omega-3 PUFAs and digestive system cancers could not be accurately assessed. In addition, although we established strict inclusion criteria, the different definitions of omega-3 PUFA intake might influence the results.

5. Conclusion
=============

In summary, n-3 PUFA intake is inversely associated with the risk of digestive system cancers, especially colorectal, esophageal, large bowel, and oral cavity/pharyngeal cancers. The association between omega-3 PUFA intake and the risk of cancer might underlie part of the difference in the incidence of cancer across populations. Future studies, particularly studies with a universal definition of omega-3 PUFA intake and prospective studies with larger sample sizes, should be assessed to explore the association between omega-3 PUFAs and the development of digestive system cancers.
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